To provide an update on the experimental models that have been developed recapitulating clinical antineutrophil cytoplasm antibody (ANCA) associated vasculitis. The application of the models in the study of pathogenesis, and the therapeutic implications of this, are covered in the article by van Timmeren and Heeringa in this issue.
INTRODUCTION
Antineutrophil cytoplasm antibodies (ANCAs) are associated with diseases characterized by relapsing necrotizing vasculitis of small-calibre blood vessels, frequently involving the kidneys and lungs with pauci-immune glomerulonephritis and pulmonary capillaritis, respectively. Many other organs may be affected and, as a result, the conditions cause significant morbidity and mortality. The precise disease triggers are not known, but clinical associations with infection have been reported, with experimental data implicating altered responses to microorganisms as potentially important initiators of autoimmune responses. ANCA are directed towards autoantigens found in neutrophil granules and monocyte lysosomes, specifically proteinase 3 (PR3) and myeloperoxidase (MPO), two molecules involved in innate immune responses to infection.
The diseases are more common in older age and although they can be treated with immunosuppressive therapies, significant adverse events occur with treatment and disease relapse still occurs in up to 50% of patients.
In order to dissect out the pathological basis of disease and, specifically, to understand the contribution of ANCA in mediating disease, animal models have been developed, which have been manipulated to try and replicate more precisely the clinical features of these conditions. By combining these models with genetically altered animals, significant inroads have been made into the understanding of key pathways involved in pathogenicity, which in some cases have led directly onto novel therapeutic trials, exemplified by the discovery of the important role of alternative pathway complement factors in disease initiation (see article by van Timmeren and Heeringa).
Development of adequate models has taken time and remains incomplete, with a lack of reproducible models of granulomatous PR3-ANCA-associated vasculitis being a major unmet need. This is in part due to the differences between human and rodent neutrophil PR3 expression. This is of critical importance as PR3-ANCA and MPO-ANCA associated diseases may have certain common features, such as the occurrence of pauci-immune glomerulonephritis, but also display many diverse characteristics, which translate into important differences in outcome and relapse, and thus influence longterm treatment. Therefore, one must be careful not to generalize the findings of experiments using MPO-ANCA to all ANCA-associated vasculitis (AAV). In addition, the models have focused predominantly on kidney involvement as the main readout, and less attention has been directed towards other organ or tissue involvement. 
RODENT MODELS OF MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASM ANTIBODY DISEASE
There have been many historical attempts at developing models of MPO-ANCA vasculitis (summarized in Fig. 1 [1] [2] [3] [7] [8] [9] [10] [11] [12] ), but most have failed on the basis of being associated with significant immune complex deposition, a major deviation from the pauci-immune characteristics of clinical disease. Spontaneous models of crescentic nephritis and vasculitis characterized by the presence of circulating MPO-ANCA have been reported, for example, the spontaneous crescentic glomerulonephritis/Kinjoh (SCG/Kinjoh) mice, but again, they are not pauci-immune and have an array of other autoantibodies besides MPO-ANCA [7] . Recent advances in this field have made use of mice, with their attendant availability of knockout and genetically manipulated strains, and rats, in particular strains that are inherently highly susceptible to glomerulonephritis. The strategies used include passive transfer of pathogenic antibody, which has proven useful in modelling the acute vascular injury response, and active immunization with MPO, which entrains both humoral and cellular elements of the immune system and consequently provides more insight into the autoimmune response and potential responses to novel therapies.
Murine models of myeloperoxidaseantineutrophil cytoplasm antibody disease
The major advance in the field came almost 10 years ago when Xiao et al. [1] developed an acute passive transfer model using purified antibody or splenocytes taken from MPO-deficient mice immunized with purified murine MPO. These were injected into wild-type or RAG-deficient recipients. The mice developed, over the course of 6-13 days, necrotizing pauci-immune glomerulonephritis and, in some cases, pulmonary capillaritis. It was noted that the splenocyte transfer recipients had glomerular immune deposits, whereas the antibody transfer recipients were pauci-immune. Therefore, virtually all subsequent work done with this model has used the passive antibody transfer strategy, even though the degree of induced disease is very much milder (reported crescent fraction 5-15% with additional stimuli). They went on to confirm that the development of glomerulonephritis was dependent on B cells rather than T cells and required the presence of neutrophils [13] . Further recent refinements of this model by Huugen et al. [14] have shown that it is augmented by the addition of lipopolysaccharide (LPS), mimicking the effects of infection exacerbating autoimmune phenomenona. Additional experiments went on to show that the principal effect of the LPS was mediated via tumour necrosis factor-a. By testing this model in different mouse strains, Xiao et al. have reported in abstract form that the genetic background of the mice has a profound effect on the severity of the model, with 129S7 mice developing worse disease than C57BL/6 mice (in which the model was first generated) [15 && ]. In addition, through the use of knockout mice, the KEY POINTS Current animal models of vasculitis have defined key pathogenic pathways and led to the development of potential new therapies.
Current models are limited, as they replicate only some features of antineutrophil cytoplasm antibody (ANCA) associated diseases.
Proteinase 3-ANCA-associated vasculitis and granulomatous disease have not yet been adequately modelled.
Models need validation and replication. ]. Finally, the model demonstrated a critical role for alternative, but not classical, complement components in disease induction [16] , which was surprising given the lack of clinical evidence of complement consumption in AAV. This has led to the development of clinical trial protocols of alternative complement blockade in AAV. As these small molecule inhibitors of C5a receptor are only active against the human form of the receptor, Xiao et al. [17] amended the murine anti-MPO transfer model by generating mice transgenic for the human C5a receptor. This allowed them to test the inhibitor in the murine model and demonstrate its efficacy in reducing renal disease.
In a modification of this model, using a bone marrow transplant approach, the same group demonstrated that MPO expression on haematopoietic cells is necessary for disease induction [18] . This relied upon immunization of the MPO-deficient mice with murine MPO, then subjecting the mice to lethal irradiation, followed by transfer of either MPO-expressing or MPO-deficient bone marrow. Only the former transfer resulted in disease, manifested as necrotizing glomerulonephritis. This model, with its various refinements, has revolutionized our understanding of the mechanisms of acute anti-MPO-induced vascular injury. However, it has limitations as these are not autoimmune models and, critically, they are downstream of the break in clinical tolerance, restricting some of the potential insights into disease initiation. A slightly different murine strategy for modelling MPO autoimmunity was adopted by the group of Holdsworth and Kitching. They immunized C57BL/6 mice with MPO in adjuvant (both human and murine MPO have been used), generating cellular and humoral anti-MPO responses, followed by challenge with low-dose subnephritogenic nephrotoxic serum, to localize the immune response to the glomeruli [2] . In contrast to the passive MPO model, this technique is dependent on T-cell immunity, as m-chain deficient mice (which are unable to make antibody) remain susceptible, whilst depletion of CD4 þ T cells, 10 days following immunization, attenuates disease without altering ANCA titres [2] . The suggestion is that this model relies on deposition of MPO in the glomerular circulation, and that there is a cellular immune response towards the deposited MPO. This model has been used to demonstrate that IL-17 appears to be critical for disease induction [19 & ], as discussed in more detail by van Timmeren and Heeringa, and corroborates the clinical findings of elevated IL-17 levels in patients with ANCA-associated vasculitis [20 & ]. This model also demonstrated the importance of innate immune pathway stimulation as a co-stimulus for disease induction [21 & ], again mimicking the influence of infection and Toll-like receptor signalling on development of glomerulonephritis.
Rat models of myeloperoxidaseantineutrophil cytoplasm antibody disease
A model of MPO-ANCA-associated AAV has been induced by immunization of the susceptible Wistar-Kyoto (WKY) rat strain with human MPO, in Complete Freund's adjuvant (CFA). This approach results in the generation of MPO-ANCA and MPO-reactive T cells [22] with the development of a crescentic, pauci-immune glomerulonephritis, with pulmonary capillaritis in a proportion of animals [23] . The induced antihuman MPO antibodies cross-react with rat MPO, which displays significant homology to the human molecule. In this model, ANCA-IgG has not been demonstrated to transfer disease (although it does increase leukocyte-endothelial interaction) [24] , but the model has clearly shown that the composition of the adjuvant (providing the innate immune stimulation) and the genetic background of the rat are critical in determining the severity and susceptibility of disease [23] . Lewis rats, which share the same Rt1 locus (MHC) as the WKY strain, do not develop vasculitis or glomerulonephritis, despite achieving similar levels of anti-MPO antibodies, demonstrating that non-MHC genes are important in mediating the pathogenic potential of the MPO-ANCA. The significant genetic differences conferring susceptibility to other forms of glomerulonephritis in these rats have in part been described, and relate largely to differences in activatory Fc receptors [25] . The role of these genetic loci as susceptibility factors is currently being investigated in congenic Lewis/WKY animals using the autoimmune MPO model.
These rodent models at first appear somewhat inconsistent, with one demonstrating ANCA or MPO-reactive B cells to be sufficient for disease induction, whilst another suggests that anti-MPO T-cell reactivity may be sufficient and that B cells are not required. In addition, although the murine Tcell-mediated model implicates deposited MPO directing a delayed-type hypersensitivity response within the kidney, this does not appear to be the main mechanism in the rat MPO autoimmune model, as no evidence of deposited MPO was found [3] . These models are also somewhat contrived. For example, MPO-ANCA is induced in MPO-deficient animals, thereby inducing an alloimmune response to an antigen that the animal has never before been exposed to, which is clearly different from the mechanism in which autoantibodies develop. Although it has not been formally tested, these antibodies presumably have different affinity and avidity to autoantibodies developing in the context of AAV, whilst the cell-mediated models require immunization with adjuvant to break immune tolerance. However, considered together, these rodent models demonstrate that vasculitis, as manifested by pulmonary and renal disease, may be induced if a sufficient anti-MPO immunity threshold is achieved. In reality, patients rarely display an exclusively T or B cell immune response, both arms of the adaptive immune response being activated. Therefore, these reductionist models can provide critical insights into the individual mechanisms of disease induction, whilst not being capable of defining them all. In particular, none can explain why immune tolerance to self-antigens is broken in the first instance, with consequent destructive anti-MPO reactivity.
RODENT MODELS OF PROTEINASE 3-ANTINEUTROPHIL CYTOPLASM ANTIBODY DISEASE
It is of interest that, in contrast, no spontaneous models of glomerulonephritis or of vasculitis associated with anti-PR3 antibodies, or indeed of PR3-ANCA in association with other autoantibodies, have been reported in rodents. This is likely to be related in part to the differences between human and rodent PR3 cellular expression. Despite immunizing rats and mice with combinations of human or murine PR3, or chimeric molecules, and proving that PR3-ANCA were induced, Van der Geld et al. [26] could not demonstrate the generation of vasculitis. Using a different approach, and attempting to replicate the success of the MPO-ANCA model generated in Chapel Hill by Jennette's group, Pfister et al. [27] immunized PR3 and neutrophil elastase deficient mice with murine PR3 and transferred the resultant antibodies into LPS-primed mice. No significant effect was seen following PR3-ANCA transfer with regards to renal or pulmonary pathology. However, a mild increase in panniculitis was seen following intradermal tumour necrosis factor injection and PR3-ANCA transfer compared with controls. There was no further development in this area until recently, when Primo et al. [4 & ] used another modification of the immunization and transfer method. This group reported successful transfer of PR3-ANCA-producing splenocytes, isolated from recombinant murine PR3 immunized autoimmune prone nonobese diabetic (NOD) mice, into naïve NOD-SCID recipients (which lack endogenous T and B cells). Interestingly, the immunized NOD mice developed PR3-ANCA, but no disease despite prolonged follow up, whereas the NOD-SCID mice which received the PR3-reactive splenocytes rapidly developed signs of disease with vasculitis and necrotizing crescentic glomerulonephritis. There was no granuloma formation observed. By contrast, C57BL/6-RAG mouse recipients of the same splenocytes did not develop disease. These findings suggest that there are protective mechanisms operating in immunized NOD mice, possibly through regulatory lymphocyte populations, whereas the genetic background and degree of immunodeficiency play a role in disease susceptibility. Of note, the presence or absence of glomerular immune deposits is not commented upon in this report, although, given that the splenocyte transfer technique was the same as that used by Xiao et al., it is probable that such deposits were present, thereby potentially limiting the applicability of the results to human anti-PR3-associated AAV.
More recently, Little et al. [5 && ] have reported, in abstract form, the use of humanized immunodeficient NOD-SCID IL-2 receptor knockout mice, which received human haematopoietic stem cells and developed a human-mouse chimeric immune system. These mice developed mild glomerulonephritis and lung haemorrhage (but no evidence of granulomata) following passive transfer of PR3-ANCA containing IgG derived from patients with severe systemic vasculitis. These exciting developments open the way for further investigation of pathogenic mechanisms and definition of immune requirements for induction of anti-PR3-associated vasculitis.
OTHER SIGNIFICANT RODENT MODELS
Although not strictly a model of AAV, a model of pauci-immune crescentic glomerulonephritis associated with immunity against lysosomal membrane protein-2 (LAMP-2) deserves mention [6] . This model was generated by injecting antibodies directed against this protein into glomerulonephritis-susceptible WKY rats with resultant pauciimmune crescent formation in 20% of glomeruli. No immunity against either PR3 or MPO was observed in the recipients; however, labile anti-LAMP-2 antibodies have been reported in some cohorts of patients with pauci-immune crescentic glomerulonephritis. Furthermore, building upon the observation that a bacterial fimbrial protein, FimH, and LAMP-2 share sequence homology, the authors observed that 90% of WKY rats immunized with FimH developed pauci-immune focal necrotizing glomerulonephritis with crescents. This important work provides evidence for molecular mimicry between bacterial and human proteins as a potential mechanism for breaking tolerance and generating autoimmunity and suggests a reason for the frequently observed association between infection and systemic vasculitis. The fact that an identical renal lesion can be induced in rats without MPO or PR3 antibodies serves as a salutary reminder that this pathological appearance is the result of a final common pathway that may arise as a consequence of diverse insults. Debate continues as to the role of these antibodies in patients with crescentic glomerulonephritis.
CONCLUSION
By inducing an abnormal immune response to MPO, various research groups have been able to generate pathology in mice and rats that mimics in many respects that seen in human MPO-ANCA AAV, although most models exhibit much milder disease than that usually seen in patients. Passive transfer of pathogenic antibody has proven a useful tool for investigating the molecular mechanisms underpinning the acute vascular injury and supports the concept that anti-MPO antibodies, in conjunction with neutrophils, are capable of inducing such injury in man. This provides a rationale for therapeutic strategies that aim to remove these antibodies, such as plasma exchange and rituximab. Active immunization of mice and rats with MPO has provided a more accurate model of an immune response that involves both cellular and humoral arms of the immune system, allowing investigation of the role of T cells and, specifically, the TH17 axis. Such active immunization strategies are also well suited to long-term therapeutic trials of novel agents, although for this to become truly useful in the R&D pathway, the disease phenotype of these models will need to be made more severe. Modelling of anti-PR3-associated disease in animals is much less advanced and, by virtue of the differences in PR3 structure and expression, will probably rely in the future on the use of humanized in-vivo systems.
Generation of an animal model that incorporates both anti-PR3-associated vasculitis and granuloma formation is a major challenge facing researchers over the next decade.
